PHARMAC seeking views on new type 2 diabetes medicines

PHARMAC

9 September 2020 - PHARMAC is looking at funding two new medicines with substantial health benefits for up to 50,000 New Zealanders with type 2 diabetes mellitus.

The three medicines are empagliflozin (brand name Jardiance), empagliflozin with metformin (brand name Jadiamet), and dulaglutide (brand name Trulicity).

Evidence suggests these medicines do more than just reduce sugar levels in people with type 2 diabetes mellitus. They can also help address type 2 diabetes-related complications like kidney and heart disease.

Read PHARMAC press release

Michael Wonder

Posted by:

Michael Wonder